Successful therapeutic use of rituximab in refractory membranous glomerulonephritis

Clin Nephrol. 2006 Jul;66(1):54-7. doi: 10.5414/cnp66054.


We present the case of a 57-year-old man with nephrotic syndrome secondary to idiopathic membranous glomerulonephritis unsuccessfully treated with angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor antagonist (ARA), prednisone and chlorambucil. After treatment with rituximab, we observed a progressive decrease of proteinuria and normalization of serum albumin. 18 months after treatment, he remained in remission. No adverse reactions to rituximab were noted throughout follow-up.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / metabolism
  • B-Lymphocytes / immunology
  • Glomerulonephritis, Membranous / blood
  • Glomerulonephritis, Membranous / immunology
  • Glomerulonephritis, Membranous / therapy*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Nephrotic Syndrome / blood
  • Nephrotic Syndrome / immunology
  • Nephrotic Syndrome / therapy
  • Rituximab
  • Time Factors


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Immunologic Factors
  • Rituximab